Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines

Vaccine

Volumn 27, Issue 51, 2009, Pages 7149-7155

  Franka, Richard ^a   Wu, Xianfu ^a   Jackson, Felix R ^a   Velasco Villa, Andres ^a   Palmer, Dustyn P ^a   Henderson, Heather ^a,b   Hayat, Wajid ^a   Green, Douglas B ^a   Blanton, Jesse D ^a   Greenberg, Lauren ^a   Rupprecht, Charles E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b District 4 Health Services   (United States)

Author keywords

Pathogenesis; Post exposure prophylaxis; Rabies vaccine; Rabies virus

Indexed keywords

DIPLOID CELL VACCINE; HYPERRAB; IMOGRAM; INACTIVATED VACCINE; LIVE VACCINE; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; RABIES VIRUS; RHESUS MONKEY; SPINAL CORD; SURVIVAL; SYRIAN HAMSTER; THERAPY DELAY; VIRUS PATHOGENESIS;

ANIMALS; ANTIBODIES, VIRAL; CRICETINAE; FEMALE; IMMUNIZATION SCHEDULE; MACACA MULATTA; MESOCRICETUS; MICE; MICE, INBRED ICR; RABIES; RABIES VACCINES; RABIES VIRUS; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 71549165758     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.034     Document Type: Article

References (49)

1. Hattwick M.A.W., Weis T.T., Stechschulte C.J., Baer G.M., and Gregg M.B. Recovery from rabies. Ann Intern Med 76 (1972) 931-942
2. Theodorides J. Histoire de la rage (1986), Cave Canem, Paris, Mason
3. Hemachudha T., and Wilde H. Survival after treatment of rabies. N Engl J Med 353 (2005) 1068-1069
4. Neville J. Rabies in the ancient world. In: King A.A., Fooks A.R., Aubert M., and Wandeler A.I. (Eds). Historical perspective of rabies in Europe and Mediterranean basin (2004), OIE, Paris 1-13
5. Baer G.M. The history of rabies. In: Jackson A.C., and Wunner W.H. (Eds). Rabies. 2nd ed. (2007), Academic Press, San Diego 1-22
6. Jackson A.C. Human disease. In: Jackson A.C., and Wunner W.H. (Eds). Rabies. 2nd ed. (2007), Academic Press, San Diego 309-340
7. Jackson A.C., Warrell M.J., Rupprecht C.E., Ertl H.C.J., Dietzschold B., O'Reilly M., et al. Management of rabies in humans. Clin Infect Dis 36 (2003) 60-63
8. Willoughby Jr. R.E., Tieves K.S., Hoffman G.M., Ghanayem N.S., Amlie-Lefond C.M., Schwabe M.J., et al. Survival after treatment of rabies with induction of coma. N Engl J Med 352 (2005) 2508-2514
9. Rupprecht C.E., Willoughby R., and Slate D. Current and future trends in the prevention, treatment and control of rabies. Expert Rev Anti Infect Ther 4 (2006) 1021-1038
10. World Health Organization. WHO Expert Consultation on Rabies. 1st Report (WHO Technical Report Series, No. 931). Geneva, Switzerland; 2005.
11. CDC. Human rabies prevention-United States, 2008. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57 RR-3 (2008) 1-28
12. Hanlon C.A., DeMattos C.A., DeMattos C.C., Niezgoda M., Hooper D.C., Koprowski H., et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19 (2001) 3834-3842
13. Malerczyk C., Selhorst T., Tordo N., Moore S., and Müller T. Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains. Vaccine 27 39 (2009) 5320-5325
14. Hooper D.C., Morimoto K., Bette M., Weihe E., Koprowski H., and Dietzschold B. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 72 (1998) 3711-3719
15. Lafon M. Human rabies vaccines. In: Jackson A.C., and Wunner W.H. (Eds). Rabies. 2nd ed. (2007), Academic Press, San Diego 489-504
16. Briggs D.J. Human rabies vaccines. In: Jackson A.C., and Wunner W.H. (Eds). Rabies. 2nd ed. (2007), Academic Press, San Diego 505-515
17. Rupprecht C.E., Briggs D., Brown C.M., Franka R., Katz S.L., Kerr H.D., et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 27 (2009) 7141-7148
18. Wunner W.H., Dietzschold B., Curtis P.J., and Wiktor T.J. Rabies subunit vaccines. J Gen Virol 64 (1983) 1649-1656
19. Lodmell D.L., Esposito J.J., and Ewalt L.C. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals. Vaccine 22 (2004) 3329-3333
20. Fujii H., Takita-Sonoda Y., Mifune K., Hirai K., Nishizono A., and Mannen K. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein. J Gen Virol 75 (1994) 1339-1344
21. Wunner W.H. Next generation rabies vaccines. In: Jackson A.C., and Wunner W.H. (Eds). Rabies. 2nd ed. (2007), Academic Press, San Diego 531-544
22. Faber M., Li J., Kean R.B., Hooper D.C., Alugupalli K.R., and Dietzschold B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc Natl Acad Sci USA 106 (2009) 11300-11305
23. Bankovskiy D., Safonov G., and Kurilchuk Y. Immunogenicity of the ERA G 333 rabies virus strain in foxes and raccoon dogs. Dev Biol (Basel) 131 (2008) 461-466
24. Dean D.J., Abelseth M.K., and Athanasiu P. The fluorescence antibody test. In: Meslin F.X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies. 4th ed. (1996), World Health Organization, Geneva pp. 88-93
25. Trimarchi C.V., and Smith J.S. Diagnostic evaluation. In: Jackson A.C., and Wunner W.H. (Eds). Rabies. 1st ed. (2002), Academic Press, New York, N.Y pp. 307-349
26. Smith J.S., Yager P.A., and Baer G.M. A rapid tissue culture test for determining rabies neutralizing antibody. Monogr Ser World Health Organ 23 (1973) 354-357
27. Griffin D.E., Levine B., Tyor W.R., and Irani D.N. The immune response in viral encephalitis. Semin Immunol 4 (1992) 111-119
28. Koski C.L. Immune interactions in the peripheral nervous system. In: Latov N., Wokke J.H.J., and Kelly Jr. J.J. (Eds). Immunology and infectious diseases of the peripheral nerves (1998), Cambridge University Press 3-28
29. Lafon M. Modulation of the immune response in the nervous system by rabies virus. Curr Top Microbiol Immunol 289 (2005) 239-258
30. Finke S., and Conzelmann K.K. Replication strategies of rabies virus. Virus Res 111 (2005) 120-131
31. Brzózka K., Finke S., and Conzelmann K.K. Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J Virol 80 (2006) 2675-2683
32. Baer G.M., Shanthaveerappa T.R., and Bourne G.H. Studies on the pathogenesis of fixed rabies virus in rats. Bull World Health Organ 33 (1965) 783-794
33. Shankar V., Dietzschold B., and Koprowski H. Direct entry of rabies virus into the central nervous system without prior local replication. J Virol 65 (1991) 2736-2738
34. Tsiang H., Ceccaldi P.E., and Lycke E. Rabies virus infection and transport in human sensory dorsal root ganglia neurons. J Gen Virol 72 (1991) 1191-1194
35. Oztas E. Neuronal tracing. Neuroanatomy 2 (2003) 2-5
36. Conzelmann K.K. Transcriptional activation of alpha/beta interferon genes: interference by nonsegmented negative-strand RNA viruses. J Virol 79 (2005) 5241-5248
37. Wang Z.W., Sarmento L., Wang Y., Li X.Q., Dhingra V., Tseggai T., et al. Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J Virol 79 (2005) 12554-12565
38. Dietzschold B., Tollis M., Lafon M., Wunner W.H., and Koprowski H. Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology 161 (1987) 29-36
39. Hooper D.C., Phares T.W., Fabis M.J., and Roy A. The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl Trop Dis 3 10 (2009) e535
40. Phares T.W., Kean R.B., Mikheeva T., and Hooper D.C. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from central nervous system. J Immunol 176 (2006) 7666-7675
41. Roy A., Phares T.W., Koprowski H., and Hooper D.C. Failure to open the blood-brain barrier and deliver immune effectors to central nervous system tissues leads to the lethal outcome of silver-haired bat rabies virus infection. J Virol 81 (2007) 1110-1118
42. Roy A., and Hooper D.C. Immune evasion by rabies viruses through the maintenance of blood-brain barrier integrity. J Neurovirol 14 (2008) 401-411
43. Lassman H., Zimprich F., Rossler R., and Vass K. Inflammation in the nervous system: basic mechanism and immunological concepts. Rev Neurol 147 (1991) 763-781
44. McGavern D.B., Homann D., and Oldstone M.B.A. T cells in the central nervous system: the delicate balance between viral clearance and disease. J Infect Dis 186 Suppl. 2 (2002) S145-S151
45. Oldstone M.B.A. Future trends in neuroVirology: neuronal survival during viral infection and analysis of virus-specific T cell in central nervous tissues. J Neurovirol 10 (2004) 207-215
46. Merigan T.C., Baer G.M., Winkler W.G., Bernard K.W., Gibert C.G., Chany C., et al. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Ann Neurol 16 (1984) 82-87
47. Schmiedel S., Panning M., Lohse A., Kreymann K.G., Gerloff C., Burchard G., et al. Case report on fatal human rabies infection in Hamburg, Germany, March 2007. Euro Surveill 12 5 (2007) E070531.5
48. Warrell M.J., White N.J., Looareesuwan S., Phillips R.E., Suntharasamai P., Chanthavanich P., et al. Failure of interferon alfa and ribavirin in rabies encephalitis. Br Med J 299 (1989) 830-833
49. Kureishi A., Xu L.Z., Wu H., and Stiver H.G. Rabies in China: recommendations for control. Bull World Health Organ 70 (1992) 443-450